시장보고서
상품코드
1193240

백반 치료 시장 : 약제 클래스 타입별, 종류별, 유통 채널별 - 세계 기회 분석과 산업 예측(2021-2031년)

Vitiligo Treatment Market By Drug Class Type, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

발행일: | 리서치사: Allied Market Research | 페이지 정보: 영문 270 Pages | 배송안내 : 2-3일 (영업일 기준)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 백반 치료 시장은 2021년에 4억 1,054만 달러에서 2022-2031년간 CAGR 4.3%를 기록하고, 2031년에는 6억 2,582만 달러에 달할 것으로 예측됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

  • 시장 정의와 범위
  • 주요 조사 결과
    • 주요 투자 포켓
  • Porter's Five Forces 분석
  • 주요 기업의 포지셔닝
  • 시장 역학
    • 성장 촉진요인
    • 성장 억제요인
    • 기회
  • COVID-19 영향 분석

제4장 백반 치료 시장 : 약제 클래스 타입별

  • 개요
    • 시장 규모 및 예측
  • 코르티코스테로이드
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모 및 예측 : 지역별
    • 시장 분석 : 국가별
  • 칼시뉴린 억제제
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 기타
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제5장 백반 치료 시장 : 종류별

  • 개요
    • 시장 규모와 예측
  • 세그먼트
    • 주요 시장 동향, 성장 촉진요인과 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 논세그먼트
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제6장 백반 치료 시장 : 유통 채널별

  • 개요
    • 시장 규모 및 예측
  • 병원내 약국
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 드럭스토어, 소매 약국
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별
  • 온라인 프로바이더
    • 주요 시장 동향, 성장 촉진요인, 기회
    • 시장 규모와 예측 : 지역별
    • 시장 분석 : 국가별

제7장 백반 치료 시장 : 지역별

  • 개요
    • 시장 규모와 예측
  • 북미
    • 주요 동향과 기회
    • 북미 시장 규모와 예측 : 약제 클래스 타입별
    • 북미 시장 규모와 예측 : 종류별
    • 북미 시장 규모와 예측 : 유통 채널별
    • 북미 시장 규모와 예측 : 국가별
      • 미국
      • 캐나다
      • 멕시코
  • 유럽
    • 주요 동향과 기회
    • 유럽 시장 규모와 예측 : 약제 클래스 타입별
    • 유럽 시장 규모와 예측 : 종류별
    • 유럽 시장 규모와 예측 : 유통 채널별
    • 유럽 시장 규모와 예측 : 국가별
      • 독일
      • 프랑스
      • 영국
      • 이탈리아
      • 스페인
      • 기타 유럽
  • 아시아태평양
    • 주요 동향과 기회
    • 아시아태평양 시장 규모와 예측 : 약제 클래스 타입별
    • 아시아태평양 시장 규모와 예측 : 종류별
    • 아시아태평양 시장 규모와 예측 : 유통 채널별
    • 아시아태평양 시장 규모와 예측 : 국가별
      • 일본
      • 중국
      • 호주
      • 인도
      • 한국
      • 기타 아시아태평양
  • LAMEA
    • 주요 동향과 기회
    • LAMEA 시장 규모와 예측 : 약제 클래스 타입별
    • LAMEA 시장 규모와 예측 : 종류별
    • LAMEA 시장 규모와 예측 : 유통 채널별
    • LAMEA 시장 규모와 예측 : 국가별
      • 브라질
      • 사우디아라비아
      • 남아프리카공화국
      • 기타 LAMEA

제8장 기업 상황

  • 서론
  • 주요 성공 전략
  • 주요 10개사 제품 매핑
  • 경쟁 대시보드
  • 경쟁 히트맵
  • 주요 발전

제9장 기업 개요

  • Arcutis Biotherapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Belcher Pharmaceuticals, LCC
  • Celgene Corporation
  • clinuvel pharmaceuticals ltd
  • Dr. Reddy's Laboratories Ltd
  • Glenmark Pharmaceuticals Ltd
  • Mylan N.V.
  • Panacea Biotec Ltd
  • Pfizer Inc.
  • Strides Pharma Science Limited
KSM 23.03.17

The global vitiligo treatment market was valued at $410.54 million in 2021, and is projected to reach $625.82 million by 2031, registering a CAGR of 4.3% from 2022 to 2031. 

Vitiligo is a long-term condition in which pale to white patches develop on the skin. In addition, hair on these areas of skin lose their pigment and appear white. This is caused by lack of melanin, which is a natural pigment present in the skin. Lack of melanin can lead to development of white patches on the skin primarily on face, neck, and hands. The onset of vitiligo starts in mid-twenties, however in some individuals it can appear at any age. It is an autoimmune disorder in which a person's immune system attack the melanocytes. These melanocytes are responsible for melanin synthesis. The treatment for vitiligo is based on restoring the skin color.

The vitiligo treatment market growth is driven by increase in patients suffering from vitiligo conditions. For instance, according to National Center for Biotechnology Information (NCBI) in 2017, a relatively high prevalence of vitiligo was found in Africa region. Furthermore, surge in R&D activities for effective vitiligo treatment and rise in awareness regarding vitiligo conditions are the factors that significantly contribute toward the growth of the market.

However, strict regulatory rules and long procedures for drug approvals hinder the growth of the market. On the other side, increase in healthcare expenditure is expected to create opportunities for the growth of the market.

The vitiligo treatment market is segmented into drug class type, type, distribution channel, and region. By drug class type the market is categorized into corticosteroids, calcineurin inhibitor, and others. Depending on type, it is fragmented into segmental and non-segmental. On the basis of distribution channel, it is divided into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global vitiligo treatment market are Arcutis Biotherapeutics, Astellas Pharma Inc., Bausch Health Companies Inc. (Bausch+Lomb Inc.), Bristol-Meyers Squibb (Celegen), Dermavant Science Inc., Dr. Reddy's Laboratories Ltd, Incyte Corporation, Merck kGaA, Pfizer Inc., Viatirs Inc. (Mylan N.V.).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vitiligo treatment market analysis from 2021 to 2031 to identify the prevailing vitiligo treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vitiligo treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vitiligo treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Segmental
  • Non Segmental

By Distribution Channel

  • Drug Stores and Retail Pharmacies
  • Online Providers
  • Hospital Pharmacies

By Drug Class Type

  • Corticosteroids
    • Route of Administration
    • Topical Route
    • Oral and Systemic Route
  • Calcineurin Inhibitor
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Arcutis Biotherapeutics
    • Astellas Pharma Inc.
    • Bausch Health Companies Inc.
    • Belcher Pharmaceuticals, LCC
    • Celgene Corporation
    • clinuvel pharmaceuticals ltd
    • Dr. Reddy's Laboratories Ltd
    • Glenmark Pharmaceuticals Ltd
    • Mylan N.V.
    • Panacea Biotec Ltd
    • Pfizer Inc.
    • Strides Pharma Science Limited

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Corticosteroids
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Corticosteroids Vitiligo Treatment Market by Route of Administration
      • 4.2.4.1 Topical Route Market size and forecast, by region
      • 4.2.4.2 Oral and Systemic Route Market size and forecast, by region
  • 4.3 Calcineurin Inhibitor
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: VITILIGO TREATMENT MARKET, BY TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Segmental
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Non Segmental
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: VITILIGO TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class Type
      • 7.2.2.1 North America Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.2.3 North America Market size and forecast, by Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Class Type
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Class Type
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Class Type
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class Type
      • 7.3.2.1 Europe Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.3.3 Europe Market size and forecast, by Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Class Type
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Class Type
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Class Type
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Class Type
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Class Type
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Class Type
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class Type
      • 7.4.2.1 Asia-Pacific Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.4.3 Asia-Pacific Market size and forecast, by Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Class Type
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Class Type
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Drug Class Type
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Drug Class Type
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Class Type
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Class Type
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class Type
      • 7.5.2.1 LAMEA Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.5.3 LAMEA Market size and forecast, by Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Class Type
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Class Type
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Class Type
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Class Type
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Arcutis Biotherapeutics
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Astellas Pharma Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Belcher Pharmaceuticals, LCC
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Celgene Corporation
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 clinuvel pharmaceuticals ltd
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Dr. Reddy's Laboratories Ltd
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Glenmark Pharmaceuticals Ltd
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Mylan N.V.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Panacea Biotec Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Pfizer Inc.
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 Strides Pharma Science Limited
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제